Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM NYSEARCA:SDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$9.39+1.3%$9.10$0.06▼$14.93$7.17M0.98559,959 shs5,413 shsSDYSPDR S&P Dividend ETF$139.84+0.9%$134.87$119.83▼$144.45$20.53B0.86257,419 shs188,123 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech+1.21%+1.55%+0.77%+0.77%-74.42%SDYSPDR S&P Dividend ETF+0.24%+0.07%+2.26%+9.82%+9.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.4864 of 5 stars3.50.00.00.02.50.00.0SDYSPDR S&P Dividend ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.002,828.65% UpsideSDYSPDR S&P Dividend ETF 2.44Hold$140.160.23% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$146K49.14N/AN/A$0.20 per share46.95SDYSPDR S&P Dividend ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/ASDYSPDR S&P Dividend ETFN/AN/A19.85∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/ASDYSPDR S&P Dividend ETF$3.562.55%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75SDYSPDR S&P Dividend ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%SDYSPDR S&P Dividend ETF43.42%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%SDYSPDR S&P Dividend ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech20764,00068.74 millionNot OptionableSDYSPDR S&P Dividend ETFN/A146.80 millionN/ANot OptionableSDY, RPS, DWF, MNZS, and AIM HeadlinesRecent News About These CompaniesSDY Is a Popular Dividend ETF for Passive Income. But Is It the Best? - NasdaqJune 30, 2025 | nasdaq.com5 High-Yielding ETFs to Buy and Hold Forever (SDY)...June 30, 2025 | marketbeat.comSDY Is a Popular Dividend ETF for Passive Income. But Is It the Best?June 29, 2025 | fool.comSPDR Portfolio S&P Sector Neutral Dividend ETF declares quarterly distribution of $0.3040June 23, 2025 | msn.comSPDR S&P Dividend ETF declares quarterly distribution of $0.9274June 23, 2025 | msn.comSDY: Dividend Stocks Give Way To The Mag 7 In Q2 (Rating Downgrade)June 20, 2025 | seekingalpha.comShould SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar?June 2, 2025 | zacks.comIs SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now?May 26, 2025 | zacks.comTarget Earnings Troubles Call for a Diversified ApproachMay 22, 2025 | etftrends.comESDY's Holdings Imply 10% Gain PotentialMay 15, 2025 | nasdaq.comSDY SPDR® S&P Dividend ETFMay 15, 2025 | seekingalpha.comFed Stays Put, No Rush to Cut Rates: Dividend ETFs to TapMay 8, 2025 | zacks.comCGDG: The Less-Known Dividend Grower Can Beat The Market In Long TermApril 26, 2025 | seekingalpha.comVIDEO: ETF of the Week: SDYApril 22, 2025 | etftrends.comE5 Good ETFs to Invest in and ForgetApril 17, 2025 | zacks.comETF of the Week: SPDR S&P Dividend ETF (SDY)April 17, 2025 | etftrends.comETurning to Dividend ETFs for StabilityApril 14, 2025 | etftrends.comESDY: Aristocrats Can Beat In UncertaintyApril 8, 2025 | seekingalpha.comShould SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar?April 1, 2025 | zacks.comIs SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now?March 25, 2025 | zacks.comFinal Trade: SDY, TJX, ZM, GISMarch 19, 2025 | youtube.comYNew MarketBeat Followers Over TimeSDY, RPS, DWF, MNZS, and AIM Company DescriptionsAIM ImmunoTech NYSE:AIM$9.39 +0.12 (+1.29%) As of 03:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.SPDR S&P Dividend ETF NYSEARCA:SDY$139.84 +1.22 (+0.88%) As of 03:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.The SPDR S&P Dividend ETF seeks to closely match the returns and characteristics of the S&P High Yield Dividend Aristocrats Index (the Index). The Index is designed to measure the performance of the 60 highest dividend yielding S&P Composite 1500 Index constituents that have followed a managed-dividends policy of consistently increasing dividends every year for at least 25 consecutive years. The Fund generally invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds (including money market funds advised by the Adviser). SSgA Funds Management, Inc. is the investment adviser to the Fund. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Boeing's Rebound Is Well Underway—But Is It Too Late? Why Microsoft Keeps Showing Up in Congressional Portfolios Buffett's $2B+ Bet With Big Long-Term Potential Just Got Upgraded Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
